ATE373017T1 - Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen - Google Patents

Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen

Info

Publication number
ATE373017T1
ATE373017T1 AT00948934T AT00948934T ATE373017T1 AT E373017 T1 ATE373017 T1 AT E373017T1 AT 00948934 T AT00948934 T AT 00948934T AT 00948934 T AT00948934 T AT 00948934T AT E373017 T1 ATE373017 T1 AT E373017T1
Authority
AT
Austria
Prior art keywords
receptor
molecules
antigen
cell
multispecific
Prior art date
Application number
AT00948934T
Other languages
English (en)
Inventor
Yashwant Deo
Joel Goldstein
Robert Graziano
Tibor Keler
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/364,088 external-priority patent/US6365161B1/en
Application filed by Medarex Inc filed Critical Medarex Inc
Application granted granted Critical
Publication of ATE373017T1 publication Critical patent/ATE373017T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT00948934T 1999-07-30 2000-07-25 Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen ATE373017T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/364,088 US6365161B1 (en) 1995-06-07 1999-07-30 Therapeutic compounds comprised of anti-FC receptor binding agents
US52327900A 2000-03-10 2000-03-10

Publications (1)

Publication Number Publication Date
ATE373017T1 true ATE373017T1 (de) 2007-09-15

Family

ID=27002335

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948934T ATE373017T1 (de) 1999-07-30 2000-07-25 Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen

Country Status (12)

Country Link
EP (1) EP1212366B1 (de)
JP (2) JP4308470B2 (de)
KR (1) KR100816958B1 (de)
CN (1) CN1268645C (de)
AT (1) ATE373017T1 (de)
AU (1) AU779116B2 (de)
CA (1) CA2381565A1 (de)
DE (1) DE60036388D1 (de)
HK (1) HK1049170A1 (de)
IL (1) IL147766A0 (de)
MX (1) MXPA02000960A (de)
WO (1) WO2001009186A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2437814C (en) * 2001-02-12 2008-05-13 Medarex, Inc. Human monoclonal antibodies to fc alpha receptor (cd89)
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
MXPA05000403A (es) * 2002-07-15 2005-07-22 Genentech Inc Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
BG65715B1 (bg) * 2003-09-04 2009-08-31 Чавдар ВАСИЛЕВ Средство за селективно подтискане на патологични днк - специфични в клетки
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2132228B1 (de) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
KR101430627B1 (ko) 2008-05-13 2014-08-14 유니버시티 오브 캔사스 금속 추출 펩타이드(ｍａｐ) 태그 및 관련된 방법
BR112014022692A8 (pt) * 2012-03-14 2021-07-20 Regeneron Pharma molécula de ligação de antígeno multiespecífica
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
JP6473138B2 (ja) * 2013-05-03 2019-02-20 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 癌、特に前立腺癌を標的とする合成抗体模倣化合物（ＳｙＡＭ）
PL405768A1 (pl) * 2013-10-24 2015-04-27 Celther Polska Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie agonistów EGFR i HGFR jako leków przeciwnowotworowych działających na komórki nowotworowe o określonym fenotypie
NZ737726A (en) 2015-07-06 2023-03-31 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EP3241847A1 (de) * 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2-bindende antikörper
WO2018140845A2 (en) * 2017-01-27 2018-08-02 Duke University Bi-specific antibodies to cd64 and a disease antigen
CN113286613A (zh) * 2018-10-29 2021-08-20 Umc乌得勒支控股有限公司 IgA介导的通过中性粒细胞的CD47-SIRPα检查点抑制对异常细胞的杀伤
KR20220004979A (ko) 2019-03-27 2022-01-12 유엠씨 우트레크트 홀딩 비.브이. 조작된 iga 항체 및 사용 방법
WO2022098084A1 (ko) * 2020-11-06 2022-05-12 고려대학교 산학협력단 Fc 알파 수용체 결합 항체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504677A (ja) * 1989-10-20 1993-07-22 トラスティーズ オブ ダートマス カレッジ ＩｇＡレセプターに特異的なモノクロナール抗体
US6018031A (en) 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies

Also Published As

Publication number Publication date
EP1212366B1 (de) 2007-09-12
KR20020047103A (ko) 2002-06-21
WO2001009186A3 (en) 2001-05-31
CN1382157A (zh) 2002-11-27
EP1212366A2 (de) 2002-06-12
IL147766A0 (en) 2002-08-14
KR100816958B1 (ko) 2008-03-26
MXPA02000960A (es) 2002-07-02
AU779116B2 (en) 2005-01-06
JP2007119485A (ja) 2007-05-17
HK1049170A1 (zh) 2003-05-02
CN1268645C (zh) 2006-08-09
JP2003522128A (ja) 2003-07-22
WO2001009186A2 (en) 2001-02-08
DE60036388D1 (de) 2007-10-25
AU6235800A (en) 2001-02-19
JP4308470B2 (ja) 2009-08-05
CA2381565A1 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
ATE373017T1 (de) Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen
Neri et al. Immunocytokines for cancer treatment: past, present and future
Ji et al. Enhanced natural killer cell immunotherapy by rationally assembling Fc fragments of antibodies onto tumor membranes
Russell et al. Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies
CN102083850B (zh) 选择性高亲和力多齿配体及其制备方法
CA2093022C (en) Targeted immunostimulation with bispecific reagents
Prendergast et al. Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity
Binder et al. Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells
Khera et al. Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody–drug conjugates
Maruani et al. A plug-and-play approach for the de novo generation of dually functionalized bispecifics
Oude Munnink et al. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F (ab′) 2 uptake in SKBR3 tumor xenografts
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
Gadd et al. Targeted activation of toll-like receptors: conjugation of a toll-like receptor 7 agonist to a monoclonal antibody maintains antigen binding and specificity
Cho et al. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells
KR20200085942A (ko) 페르투주맙 변이체 및 그의 평가
US20180271997A1 (en) Methods and Reagents to Treat Tumor and Cancer
Simpson et al. Monoclonal antibodies for the therapy of cancer
Uvyn et al. Multivalent antibody‐recruiting macromolecules: Linking increased binding affinity with enhanced innate immune killing
Li et al. Broadening and enhancing functions of antibodies by self-assembling multimerization at cell surface
Gilabert-Oriol et al. Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells
Leal et al. Preclinical development of an anti-5T4 antibody–drug conjugate: pharmacokinetics in mice, rats, and NHP and tumor/tissue distribution in mice
WO2018231661A1 (en) Methods and reagents to treat tumor and cancer
Marquard et al. Expanding the Scope of Antibody Rebridging with New Pyridazinedione–TCO Constructs
Hong et al. Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy
EP2155250B1 (de) Kohlenhydrathaltiger pan-tumormarker

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties